Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Alphabet Inc Class A (GOOGL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Alphabet Inc Class A — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $296.34 (market cap $8.04B), while Alphabet Inc Class A trades at $372.25 (market cap $4.37T). The key difference: Alphabet Inc Class A is far larger — about 543.5× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Alphabet Inc Class A pays a 0.24% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | GOOGL | |
|---|---|---|
Market Cap | $8.04B | $4.37T |
Sector | Health | Media |
52-Week High | $339.75 | $402.62 |
52-Week Low | $241.71 | $182.00 |
Enterprise Value | $7.85B | $4.34T |
Dividend Yield | — | 0.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
Alphabet (GOOGL) stock trades at $371.52, up 5.39% in 24 hours, supported by strong earnings beats and robust financials. The technical picture is neutral with bullish moving averages, while fundamentals show impressive revenue growth to $402.84B in 2025 and a net income margin of 37.92%. Recent news highlights AI-driven growth opportunities and YouTube's subscription price increase. Analyst consensus remains overwhelmingly bullish with an average price target of $431.78.
Outlook is positive given consistent earnings outperformance, expanding AI integration across services, and strong cash flow generation. Key risks include antitrust scrutiny, competitive pressure in AI and cloud, and market volatility. The stock offers growth exposure to AI leadership but faces regulatory and execution challenges in a competitive landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Alphabet Inc Class A
Alphabet, the parent company of Google, earns nearly 90% of its revenue from Google services, mainly through advertising. Other revenue comes from subscriptions (YouTube TV, YouTube Music), platform sales (Play Store purchases), and devices (Pixel, Chromebooks, Chromecast). Google Cloud contributes around 10%, while investments in self-driving cars (Waymo), health (Verily), and internet access (Google Fiber) make up the rest.
Read more on GOOGL →
